During Q2, the company’s earnings fell to $19 million, or $1.39 a share, compared with $1.04 billion, or $4.46 a share, in the same period a year ago. Much of this decline was due to a pretax loss of approx $790 million linked with the pending sale of its wholly-owned subsidiary, KMG America Corporation (KMG).
The company, which is known to have the second largest Medicare presence, has consistently topped consensus estimate over the last four quarters.
RELATED: Humana to acquire Curo
Excluding items, the company earned $3.96 a share in Q2, that topped consensus estimate of $3.77 a share. Revenue during the quarter, rose 5.4% to $14.26 billion, higher than $14.11 billion analysts predicted.
Ever since drugstore chain CVS Health (CVS) acquired pharmacy benefits manager (PBM) Aetna (AET), there has been a major transformation in the healthcare business. Early this year, rumors were rife that Walmart (WMT) wants to deepen its existing partnership with Humana, and from the start has always considered an outright merger. If this deal goes through, it would create another major player in the PMB segment.
RELATED: Walmart’s potential deal with Humana
Shares of the company rose 27% since the beginning of the year. In the last 12 months, the stock has climbed 36%. The stock closed at $314.18 on July 31.